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 1 
ABSTRACT 1 
The National Cancer Survivorship Initiative through the National Health Service (NHS) 2 
improvement in the United Kingdom (UK) started the implementation of stratified pathways 3 
of patient-initiated follow-up (PIFU) across various tumour types. Now the initiative is 4 
continued through Living With and Beyond Cancer programme by NHS England. 5 
Evidence from non-randomised studies and systematic reviews does not demonstrate a 6 
survival advantage to the long-established practice of hospital-based follow-up (FU) 7 
regimens, traditionally over 5 years. Evidence shows that patient needs are inadequately 8 
met under the traditional hospital-based follow-up FU programmes and there is therefore 9 
an urgent need necessity to adapt pathways to the needs of patients. The assumption that 10 
hospital-based hospital-based follow-upFU is able to detect cancer recurrences early and 11 
hence improve patients’ prognosis has not been validated. A recent survey demonstrates 12 
that hospital-based follow-upFU practice across the UK varies widely, with telephone follow-13 
upFU clinics, nurse-led clinics, and PIFU becoming increasingly common. 14 
There are currently no completed randomised controlled trials in  PIFU in gGynaecological 15 
malignancies, although there is a drive towards implementing PIFUit. PIFU aims to 16 
individualise patient care, based on risk of recurrence and holistic needs, and optimising 17 
resources. The British Gynaecology Cancer Society (BGCS) wishes to provide the 18 
gynaecological oncology community with guidance and a recommendations’ statement 19 
regarding the value, indications and limitations of PIFU in endometrial, cervical, ovarian and 20 
vulva cancers in an effort to standardise practice and improve patient care. 21 
Key words: Patient initiated follow-up (PIFU), gGynaecology oOncology, follow-up (FU), 22 
gGynaecological malignancies. 23 
Precis: British Gynaecology Cancer Society (BGCS) recommendations’ statement regarding 24 
the value, indications and limitations of PIFU in endometrial, cervical, ovarian and vulvar 25 
carcinoma 26 
 27 
INTRODUCTION 28 
 2 
The British Gynaecology Cancer Society (BGCS) has issued a number of guidelines to 29 
improve the quality of care and standardise treatment and follow-up  pathways for 30 
patients with gynaecological cancer. As the practice of follow up varies widely1 31 
and is continuously evolving, the BGCS wished to implement strategies for a UK-wide 32 
implementation of patient initiated follow-up (PIFU), addressing its indications, value and 33 
limitations across all different gynaecological cancer sites.  The National Cancer Survivorship 34 
Initiative, through NHS improvement, has already implemented stratified pathways 35 
(including some patient initiated) for follow up in breast, colorectal, and prostate 36 
cancer2. Patients with early stage cancer of breast, colorectal and prostate may be 37 
offered remote surveillance and at the present time no surveillance techniques have been 38 
deemed to be effective in gynaecological cancers. 39 
Historically, patients have been kept on hospital-based follow up in dedicated outpatient 40 
clinics for 5-10 years following diagnosis and treatment for gynaecological cancer3,4. 41 
The main aims of follow-up include: detection of asymptomatic recurrences, with the 42 
assumption that this will improve prognosis; detection and management of side effects of 43 
treatment; improvement in quality of life; identification and treatment of patient concerns 44 
and anxieties around their cancer diagnosis5,6. However, there is no evidence that 45 
intensive follow-up improves survival 7-13and women often find clinical examination 46 
uncomfortable (especially vaginal examination) with 54% (48/89) experiencing increased 47 
anxiety prior to their follow up appointments6.  48 
There is evidence that the current hospital-based follow-up does not necessarily meet 49 
cancer survivors needs, failing to provide emotional support and information needs14 50 
due to limited time, resources and lack of focus on a holistic approach of the patients’ 51 
needs. A holistic approach will take account of mental and social factors as well as 52 
symptoms of the disease. In 2010 the National Cancer Survivorship Initiative (NCSI) was 53 
launched by the Department Of Health in England in collaboration with one of the UK’s 54 
largest charitable organisations, Macmillan Cancer Support, to improve the long term 55 
consequences of surviving cancer15. In more recent years, the Living With and Beyond 56 
Cancer programme16 has advocated a shift in care and support towards self-57 
management, based on individual needs and preferences, and away from the traditional 58 
single model of clinical follow-up. This approach empowers individuals to take responsibility 59 
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for their condition, supported by clinical assessment to enable early recognition of 60 
symptoms of recurrence or consequences of their treatment and a ‘Recovery Package’ that 61 
includes holistic needs assessments (performed after completion of treatment for cancer), 62 
treatment summaries, health and well-being events and cancer care reviews in primary 63 
care16. 64 
There are different follow up methods currently utilised in the UK which include hospital 65 
follow up, telephone follow up and PIFU. Hospital follow up involves seeing 66 
patients in clinics at regular intervals, whereas telephone follow up involves calling 67 
patients at a specified time at pre-determined intervals.  PIFU involves educating patients 68 
about concerning symptoms, such as vaginal bleeding, unintentional weight loss, and 69 
worsening abdominal pain or bowel/bladder symptoms. In patient-initiated follow up, 70 
patients are not given routine follow up appointments (hospital, telephone or with the 71 
General practitioner), but instead are empowered to call the gynaecological oncology 72 
team directly (often via the clinical nurse specialist with specialist cancer knowledge) if they 73 
have these symptoms and then they are fast-tracked back into the specialist care system. It 74 
is very important that patients are given written information about PIFU, which includes the 75 
contact details should they need them. Most patients find PIFU acceptable17, although 76 
younger patients and those who struggle to access healthcare (due to socio-demographic 77 
factors) may require the additional support 18of routine contact, either via hospital 78 
follow up or telephone follow up. 79 
METHODS 80 
The BGCS PIFU meeting was held on 14th March 2019 in London, UK. Experts from clinical 81 
practice (including medicine and nursing) and academia with specialist knowledge and 82 
expertise in gynaecology oncology and alternative follow up strategies reviewed 83 
available evidence from a systematic literature search in Medline, Embase CINAHL, AMED, 84 
BNI, HBE, HMIC, PsycINFO that aimed to identify significant evidence on alternatives to 85 
hospital-based follow-up. These data were presented, discussed and evaluated by the key 86 
opinion leaders. Additionally, data from a national survey of follow-up practice across the 87 
UK in gynaecological malignancies were presented. All experts agreed the consensus 88 
Commented [M3]: Please spell what this means 
Commented [NC4]: done 
 4 
guidelines for each gynaecological tumour site (cervical, ovarian, endometrial and 89 
vulva). 90 
Although there was no patient representative at the BGCS PIFU meeting, there has been 91 
positive feedback from patients within the hospitals that have already implemented the 92 
guidelines and in studies that looked at patient acceptability17-1993 
.  94 
 95 
DISCLAIMER 96 
Clinicians should always use their clinical judgement to determine if an individual patient is 97 
suitable for PIFU. These consensus recommendations have been produced as guidance for 98 
follow up pathways and are based on available evidence. Where little evidence existed, 99 
expert consensus was agreed. 100 
RESULTS 101 
PIFU guidance for each cancer type will be presented separately under the general umbrella 102 
and recommendation that only those patients who fit all of the criteria below are eligible 103 
and safe to be offered PIFU: 104 
 105 
General eligibility criteria for PIFU 
Completed primary treatment for a gGynaecological malignancy and are clinically well 
 
Patients should be willing and able to access healthcare if on PIFU 
 
They should be without significant treatment related side-effects that need ongoing management  
 
They should not have recurrent disease 
 
They should not be on active or maintenance treatment 
 
They should not be on a clinical trial where follow-up schemes are defined and limited to hospital-
based follow upFU 
 
They should not have a rare tumour with uncertain risk of recurrence and need for ongoing 
management 
They must be able to communicate their concerns without a significant language barrier or 
psychological comorbidity and have competence to agree to PIFU  
 5 
 
 106 
At the clinic visit prior to offering PIFU, patients should be provided with a careful 107 
explanation on the lack of evidence for benefit from regular follow-up visits to the hospital 108 
and the rationale for implementing a supported self-management approach (PIFU). 109 
However, for patients with significant iatrogenic side effects, which impair their quality of 110 
life and need active management, it is important that those are addressed and managed 111 
within in the clinic setting with sufficient access to other health professionals, such as 112 
gastroenterologists, urologists, endocrinologists, and psychologists. PIFU should be offered 113 
on a case-by-case basis, ensuring there are no existing unmet needs and according to their 114 
cancer type.115 
ENDOMETRIAL CANCER 116 
There are approximately 9,300 new cases of endometrial cancer in the UK and it is the 4th 117 
most common cancer in women20. There has been an increase of nearly 20% in the last 118 
10 years20, which is thought to be largely due to the sharp increase in obesity, although 119 
rarer tumours, not associated with obesity have also increased. 120 
Low risk endometrial cancer is defined by the (European Society of Medical Oncology- 121 
European Society of Gynecological Oncology) ESMO-ESGO guidelines21  as stage I 122 
endometrioid, grade 1-2 histology, with ≤50% myometrial invasion, negative for 123 
lymphovascular space invasion and hence not in need of adjuvant treatment21. 124 
Following hysterectomy and bilateral salpingo-oophorectomy, patients have their 125 
holistic needs assessment and the next steps of their journey discussed with their 126 
dedicated cancer support workers, under the coordination and guidance of the clinical nurse 127 
specialists. They can also be referred to psycho-oncological counselling services, if required 128 
and accepted by the patient. Patients are educated about symptoms that would be 129 
concerning for a recurrence, such as vaginal bleeding, worsening or persistent abdominal 130 
pain, or bladder/bowel symptoms. A population study by Salvesen over 10 years 131 
demonstrated that 653 patient consultations were needed to pick up one asymptomatic low 132 
risk endometrial cancer patient with recurrent disease12,13. Based on a very low risk 133 
of relapse without adjuvant treatment, these patients could be offered PIFU after they have 134 
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completed treatment at, or shortly after, the time of their holistic needs assessment 135 
appointment (Figure 1).136 
Intermediate risk endometrial cancer is defined by the ESMO-ESGO guidelines21 as 137 
stage I endometrioid, grade 1–2, ≥50% myometrial invasion, lymphovascular space invasion 138 
negative. These patients are commonly offered vaginal brachytherapy, without external 139 
beam radiotherapy, following their hysterectomy21. Their risk of recurrence is relatively 140 
low. Patients could be offered PIFU at the 3-month review after treatment or anytime 141 
during the first 2 years of hospital follow up. It is important for patients to be aware that 142 
they may develop late onset toxicity following brachytherapy that may not be apparent 143 
shortly after finishing their treatment. For that reason, it should be explained that they can 144 
be seen back in clinic, if their have concerns related to toxicity, as well as if they have 145 
symptoms concerning for recurrence, if they are on PIFU. Another option for these patients 146 
is telephone follow up with - randomised controlled trial level data of no physical or 147 
psychological detriment, compared to hospital follow-up, in stage I endometrial cancer22 148 
 Telephone follow-up could be seen as a useful transition between face to face hospital-149 
based appointments and PIFU. 150 
High-intermediate risk endometrial cancer is defined by the ESMO-ESGO guidelines21  as 151 
patients with grade 1–2 tumours with deep (≥50%) myometrial invasion and unequivocally 152 
positive (substantial, not focal) lymphovascular space invasion, and those with grade 3 153 
tumours with <50% myometrial invasion regardless of lymphovascular space invasion 154 
status. These patients are treated as high risk for the purpose of these guidelines, due to 155 
their higher risk of recurrent disease. High-intermediate risk endometrial cancer represents 156 
a heterogeneous group of patients, including both endometrioid and non-endometrioid 157 
tumour types, such as serous and clear cell, and ranges from stage IB grade 3 (with or 158 
without lymphovascular space invasion and with or without nodal staging) to more 159 
advanced FIGO stages21. The risk of recurrence is higher for these patients (>20%) 160 
and therefore it is suggested that they should be seen in the clinic for at least the first 2 161 
years, as this is the most frequent time for recurrence23,24. After 2 years patients 162 
could be offered PIFU for the remaining 3 years (Figure 1). Again, another alternative is 163 
telephone follow upfor the remaining 3 years.164 
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CERVICAL CANCER 165 
There are approximately 3,200 new cases of cervical cancer every year with an 166 
incidence of 12 per 100,000 in the UK25.  167 
In patients with a FIGO stage IA1 cervical cancer the British Society of Colposcopy and 168 
Cervical Pathology (BSCCP) recommend cervical cytology should be taken 6 and 12 months 169 
after treatment (hysterectomy or LLETZ) followed by annual cytology for a further 9 years 170 
before returning to routine recall until the age of 65 for those treated with LLETZ and still 171 
have a cervix27. If patients have had a hysterectomy for stage IA1 cervical cancer 172 
there are specific guidelines on cytology follow-up depending on histology of the 173 
hysterectomy specimen27. Patients who have had a hysterectomy for stage IA1 are 174 
also excluded from PIFU. 175 
In low risk patients (FIGO stage IB1) who have undergone a radical hysterectomy for 176 
treatment of cervical cancer the BGCS recommends follow-up in the clinic setting every 3-4 177 
months in the first 2 years, and then PIFU can be offered (Figure 2).  It should be noted 178 
that the BSCCP recommends vault smears at 6 and 18 months after a hysterectomy for 179 
cervical intraepithelial neoplasia (CIN)27if margins are free of CIN. However, vaginal 180 
vault cytology should not be performed following treatment for FIGO stage  ≥IA2 as it 181 
does not add significantly to the detection of recurrent disease25, 27-28. These 182 
patients have a 5-year risk of recurrence of 5.8-8%27, 29-31. However only 4-5% 183 
will have pelvic recurrences and only 1-2% can be salvaged28,31,32, although this 184 
has increased slightly with cyberknife and other techniques. In a large Danish national 185 
cohort study of 1523 patients with low-risk cervical cancer, of those with recurrent 186 
disease, 67.5% experienced a symptomatic recurrence30  Other studies have shown 187 
similar rates of symptomatic recurrent cervical cancer24. Therefore, as the majority 188 
present with symptoms, PIFU appears to be reasonable for low-risk patients. As surgery for 189 
early stage cervical cancer may cause morbidity, such as bladder dysfunction and 190 
lymphoedema, hospital follow up for the first 2 years was thought to be preferable to 191 
telephone follow up (BGCS consensus agreement). 192 
In patients with intermediate (risk of recurrence 10-20%) or high risk (risk of recurrence 193 
>20%) disease, hospital follow up, to include taking an appropriate history and clinical 194 
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examination at each visit, should be undertaken to try and detect recurrent disease. This 195 
group of patients usually have FIGO stage ≥IB2, although there are other factors that play 196 
a role in the likelihood of recurrence, such as lymph node status and lymphovascular space 197 
invasion30. Hospital follow up should be undertaken for 5 years, particularly as 198 
these patients may have significant treatment-related toxicity (Figure 2). However, it 199 
should be noted that the majority of recurrences occur within 2 years; a Norwegian national 200 
prospective observational study by Vistad et al. in 2017, which included 680 patients with 201 
gynaecological cancer recurrence, showed a mean annual incidence rate from years 3-5 of 202 
only <7%30.203 
OVARIAN CANCER 204 
There were 7,500 women who developed tubo-ovarian/primary peritoneal cancer in the UK 205 
in 2016 making it the 6th most common cancer in women34.  The majority of those who 206 
developed tubo-ovarian/primary peritoneal cancer had epithelial ovarian cancer, 207 
which relates to these guidelines. Non-epithelial ovarian cancers, such as granulosa cell 208 
tumours or germ cell tumours of the ovary, are not included in these guidelines, as they 209 
have their own distinct pathogenesis and behave differently from epithelial ovarian 210 
cancer. Fertility-preserving surgery, that includes a unilateral salpingo-oophorectomy 211 
and full surgical staging, is acceptable in young patients with stage IA (grade 1 and 2), and 212 
stage IC (grade 1) disease, as they have similar recurrence rates and overall survival to 213 
those undergoing conventional treatment35. However, these patients should be seen 214 
regularly for hospital follow up and ultrasound scans of the contralateral ovary and 215 
are excluded from PIFU.  216 
Only patients who have been adequately staged, with pelvic and para-aortic 217 
lymphadenectomy and peritoneal biopsies for an apparent stage I ovarian cancer, should 218 
be offered PIFU, so that occult higher stage cancers with higher risk of relapse, are not 219 
included36. Patients with fully staged IA/B ovarian cancer (of any grade) have a low 220 
risk of recurrence and therefore could be offered PIFU after they have completed their 221 
treatment (Figure 3). Evidence does not suggest that routine follow-up of patients with 222 
ovarian cancer improves survival37-40. A randomised phase III study OV05-EORTC 223 
5595540, which compared initiation of chemotherapy on development of elevated 224 
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CA125 versus initiation of chemotherapy on clinical/symptomatic evidence of relapse 225 
showed treatment was delayed by a median of 4.8 months in the latter group with no 226 
detriment to overall survival (HR 1.01; 95% CI 0.82–1.25; P = 0.91). Moreover, quality of 227 
life was lower in the patients that had initiation of chemotherapy on CA125 rise. However, 228 
this study took place outside the possibility of secondary cytoreductive surgery for recurrent 229 
ovarian cancer and also before the establishment of targeted and maintenance agents at 230 
relapsed disease and it is unclear whether we can translate its findings to the modern era of 231 
ovarian cancer management36,42.232 
At the follow-up appointment, symptoms should be assessed and a physical examination 233 
should be carried out in the first 3 years from completing treatment in patients with FIGO 234 
stage 2-4, as this is the most common time period in which recurrent disease develops30235 
. In years 4 and 5, in the absence of recurrent disease, patients could have the option of 236 
moving to a combination of telephone follow up with CA125 serial measurements, if 237 
deemed suitable by their clinician. There is evidence that telephone follow up in ovarian 238 
cancer is well received and the majority preferred it to hospital follow up 43. If 239 
patients are not suitable for telephone follow up and remote CA125 measurements, 240 
patients should continue hospital follow up for a minimum of 5 years after completing 241 
treatment.242 
VULVAR CANCER 243 
Vulvar cancer is rare with only 1,300 new cases in 2015 in the UK, which is less than 1% of all 244 
cancers in women44. Cancer of the vulva primarily affects older women with the 245 
highest incidence of women aged 90 or over44. The difficulty of self-examination and 246 
the increased numbers of cases in deprived areas44 leads to a greater number of 247 
vulnerable women. Therefore, the BGCS recommends that women with vulvar cancer are 248 
not suitable for PIFU (Figure 4) and should follow the traditional follow up schemes 249 
involving careful clinical examination. This should be performed by clinicians with 250 
appropriate experience, which would usually be in the hospital setting. 251 
There is no evidence for the recommendations of frequency of examinations. The ESGO 252 
expert consensus guidelines and RCOG guidelines on vulvar cancer45  recommend 3-4 253 
monthly follow-up in the first 2 years, biannually for years 3 and 4 and then annual life-long 254 
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follow-up. This is supported by a retrospective analysis of 330 patients with primary vulvar 255 
carcinoma treated at the Mayo clinic, which showed 35% of recurrences occurred more 256 
than 5 years after diagnosis with both distant and local disease46. The BGCS 257 
recommends follow up of patients with vulval cancer for at least 5 years, with longer 258 
follow-up at the discretion of the treating clinician. Patients with multi-focal vulvar 259 
intraepithelial neoplasia (VIN) or lichen sclerosis with VIN (differentitated VIN) are at high 260 
risk of multi-focal disease and more intensive follow-up may be warranted45, 47. 261 
 262 
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 276 
Endometrial Cancer Clinic-based FU Telephone FU 
+/- blood test 
PIFU 
Low risk 
 (<10% risk of 
recurrence ROR) 
If patient 
declines PIFU 
(for maximum 
of 2 years from 
end of 
treatment) 
If patient 
declines PIFU 
(for maximum 
of 2 years from 
end of 
treatment) 
Offer from end of 
treatment (after 
Holistic needs 
assessment at 3 
months) 
Intermediate risk Can be offered 
if declines PIFU 
for 2 years from 
end of 
treatment 
Can be offered 
if declines PIFU 
for 2 years from 
end of 
treatment 
offer from end of 
treatment or 
after 2 years for 
all 
High -intermediate risk For 5 years 
(either 
telephone FU or 
clinic FU) 
For 5 years 
(either 
telephone FU or 
clinic FU) 
offer from 2 years 
from end of 
treatment in 
place of 
telephone FU or 
clinic FU. 
High-risk For 5 years 
(either 
telephone FU or 
clinic FU) 
For 5 years 
(either 
telephone FU or 
clinic FU) 
offer from 2 years 
from end of 
treatment in 
place of 
telephone FU or 
clinic FU. 
 277 
Figure 1: Guidelines for follow-up in eEndometrial cancer  278 
(ROR=risk of recurrence, PIFU= patient initiated follow-up, FU=follow-up) 279 
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 281 
Cervical Cancer Clinic-based FU Telephone FU +/- 
blood test 
PIFU 
Low risk (<10% risk 
of recurrence 
ROR) excluding 
fertility sparing 
surgery/ LLETZ 
For 5 years post 
completion of 
treatment 
Not suitable Offer from 2 years 
from end of 
treatment 
Intermediate risk For 5 years post 
completion of 
treatment 
Not suitable Not suitable 
High risk For 5 years post 
completion of 
treatment 
Not suitable Not suitable 
 282 
Figure 2: Guidelines for follow-up in cCervical cancer (ROR=risk of recurrence, 283 
PIFU= patient initiated follow-up, LLETZ= large loop excision of transformation 284 
zone, FU=follow-up).) 285 
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 287 
Ovarian Cancer Clinic-based FU Telephone FU +/- 
blood test 
PIFU 
Low risk (<10% risk of 
recurrence ROR, stage 
1a/b fully staged) from 
end of treatment 
(surgery +/-chemo). 
Excluding fertility 
sparing surgery 
 
Can be offered 
if declines PIFU 
for 2 years from 
end of 
treatment 
Can be offered if 
declines PIFU for 2 
years from end of 
treatment 
Offer from end 
of treatment 
(after Holistic 
needs 
assessment at 
3 months) 
FiGO stages 1c-4 For 3 years 
from end of 
treatment 
Can be offered for 
years 4+5 from end 
of treatment 
Not suitable 
 288 
Figure 3: Guidelines for follow-up in oOvarian cancer 289 
(ROR=risk of recurrence, PIFU= patient initiated follow-up, FU=follow-up) 290 
  291 
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Options for follow-up Vulval Cancer 
PIFU for 5 years from treatment 
 
Not suitable 
Remote/telephone +/- bloods 
 
Not suitable 
Clinic-based FU  
 
Follow-up including clinical inspection 
for at least 5 years from from end of 
treatment 
 
 292 
Figure 4: Guidelines for follow-up in vVulvar l cancer 293 
(FU=follow-up, PIFU= patient initiated follow-up) 294 
  295 
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